Morgan Stanley Upgrades Qiagen to Overweight, Raises Price Target to $42

Benzinga Newsdesk www.benzinga.com Positive 91.1%

Neg 0% Neu 0% Pos 91.1%

Morgan Stanley analyst Steve Beuchaw upgrades Qiagen (NYSE:QGEN) from Equal-Weight to Overweight and raises the price target from $40 to $42.